Author name: Shamnad Basheer

Continuing from our earlier post, yesterday’s hearing saw Cipla’s counsels continue arguments before an appellate bench consisting of Justice AP Shah and Justice S. Muralidhar. The key arguments advanced were: 1. That the patent in suit (covering Erlotinib) was invalid2. That the patent, even if valid, was not infringed The “public interest” and “pricing” argument was altogether avoided by Cipla’s counsels. It appears that they may have strategically decided to downplay the “public interest” argument. (Or perhaps they make take […]

In relation to our last post detailing out the various arguments by counsels in the Roche vs Cipla matter, I was a little disturbed to learn that some of our sources (who were kind enough to speak to us about the hearings) were approached by Cipla’s counsel and castigated for their alleged role in our post. Firstly, I wish to draw the attention of this aggrieved counsel to the last sentence in our post: “Needless to state, they are not

Today was yet another momentous day in the big ticket Roche vs Cipla litigation. Abhishek Manu Singhvi, counsel for Roche (along with Parag Tripathi) closed arguments on behalf of Roche. And immediately thereafter, Arun Jaitley opened arguments on behalf of Cipla. As our readers are aware, in the first instance, a single judge of the Delhi High Court, Justice S Ravindra Bhat denied an injunction to Roche in relation to its anticancer drug “Tarceva” and permitted Cipla to continue manufacturing